MET amplification identified as a potentially actionable driver for non-small cell lung cancer

MET amplification identified as a potentially actionable driver for non-small cell lung cancer
A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC).
Camidge says many of the major developments in the treatment of non-small cell lung cancer have come from defining molecularly specific subsets of the disease for which researchers have been able to develop targeted treatments. Until now, all of these subsets have been based on either genetic mutations or gene rearrangements (where two separate genes fuse to create an oncogene).

Related Keywords

Colorado ,United States ,Marileila Varella Garcia ,D Ross Camidge ,Emily Henderson ,School Of Medicine ,University Of Colorado School Medicine ,Cu Cancer Center ,Colorado School ,Patients With ,Thoracic Oncology ,Ross Camidge ,கொலராடோ ,ஒன்றுபட்டது மாநிலங்களில் ,எமிலி ஹென்டர்சன் ,பள்ளி ஆஃப் மருந்து ,பல்கலைக்கழகம் ஆஃப் கொலராடோ பள்ளி மருந்து ,சு புற்றுநோய் மையம் ,கொலராடோ பள்ளி ,நோயாளிகள் உடன் ,தொராசி புற்றுநோயியல் ,